Literature DB >> 32208767

Quantifying Target Occupancy of Small Molecules Within Living Cells.

M B Robers1, R Friedman-Ohana1, K V M Huber2,3, L Kilpatrick4,5, J D Vasta1, B-T Berger6, C Chaudhry7, S Hill4,5, S Müller6,8, S Knapp6,8,9,10, K V Wood1,11.   

Abstract

The binding affinity and kinetics of target engagement are fundamental to establishing structure-activity relationships (SARs) for prospective therapeutic agents. Enhancing these binding parameters for operative targets, while minimizing binding to off-target sites, can translate to improved drug efficacy and a widened therapeutic window. Compound activity is typically assessed through modulation of an observed phenotype in cultured cells. Quantifying the corresponding binding properties under common cellular conditions can provide more meaningful interpretation of the cellular SAR analysis. Consequently, methods for assessing drug binding in living cells have advanced and are now integral to medicinal chemistry workflows. In this review, we survey key technological advancements that support quantitative assessments of target occupancy in cultured cells, emphasizing generalizable methodologies able to deliver analytical precision that heretofore required reductionist biochemical approaches.

Keywords:  NanoBRET; SAR; chemical proteomics; energy transfer; structure–activity relationship; target engagement; target occupancy

Mesh:

Substances:

Year:  2020        PMID: 32208767     DOI: 10.1146/annurev-biochem-011420-092302

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  10 in total

1.  Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.

Authors:  Agatha Lyczek; Benedict-Tilman Berger; Aziz M Rangwala; YiTing Paung; Jessica Tom; Hannah Philipose; Jiaye Guo; Steven K Albanese; Matthew B Robers; Stefan Knapp; John D Chodera; Markus A Seeliger
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-16       Impact factor: 11.205

2.  Precision Targeting of Endogenous Epidermal Growth Factor Receptor (EGFR) by Structurally Aligned Dual-Modifier Labeling.

Authors:  Ivan de Jesus Salazar-Estrada; Karthik Shantharam Kamath; Fei Liu
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-19

Review 3.  Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Yonglan Liu; Chung-Jung Tsai; Hyunbum Jang
Journal:  J Mol Biol       Date:  2022-04-01       Impact factor: 6.151

Review 4.  An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters.

Authors:  Vojtech Dvorak; Tabea Wiedmer; Alvaro Ingles-Prieto; Patrick Altermatt; Helena Batoulis; Felix Bärenz; Eckhard Bender; Daniela Digles; Franz Dürrenberger; Laura H Heitman; Adriaan P IJzerman; Douglas B Kell; Stefanie Kickinger; Daniel Körzö; Philipp Leippe; Thomas Licher; Vania Manolova; Riccardo Rizzetto; Francesca Sassone; Lia Scarabottolo; Avner Schlessinger; Vanessa Schneider; Hubert J Sijben; Anna-Lena Steck; Hanna Sundström; Sara Tremolada; Maria Wilhelm; Marina Wright Muelas; Diana Zindel; Claire M Steppan; Giulio Superti-Furga
Journal:  Front Pharmacol       Date:  2021-08-10       Impact factor: 5.988

5.  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Authors:  Huiyu Ren; Nicole A Bakas; Mitchell Vamos; Apirat Chaikuad; Allison S Limpert; Carina D Wimer; Sonja N Brun; Lester J Lambert; Lutz Tautz; Maria Celeridad; Douglas J Sheffler; Stefan Knapp; Reuben J Shaw; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2020-11-17       Impact factor: 7.446

6.  Resistance to kinase inhibition through shortened target engagement.

Authors:  Aziz M Rangwala; Benedict-Tilman Berger; Matthew B Robers; Stefan Knapp; Markus A Seeliger
Journal:  Mol Cell Oncol       Date:  2022-01-22

Review 7.  Trends in kinase drug discovery: targets, indications and inhibitor design.

Authors:  Misty M Attwood; Doriano Fabbro; Aleksandr V Sokolov; Stefan Knapp; Helgi B Schiöth
Journal:  Nat Rev Drug Discov       Date:  2021-08-05       Impact factor: 84.694

8.  Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3.

Authors:  Martin Schröder; Panagis Filippakopoulos; Martin P Schwalm; Carla A Ferrer; David H Drewry; Stefan Knapp; Apirat Chaikuad
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

9.  Single tracer-based protocol for broad-spectrum kinase profiling in live cells with NanoBRET.

Authors:  Matthew B Robers; Jennifer M Wilkinson; James D Vasta; Lena M Berger; Benedict-Tilman Berger; Stefan Knapp
Journal:  STAR Protoc       Date:  2021-09-15

10.  Assessing target engagement using proteome-wide solvent shift assays.

Authors:  Jonathan G Van Vranken; Jiaming Li; Dylan C Mitchell; José Navarrete-Perea; Steven P Gygi
Journal:  Elife       Date:  2021-12-08       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.